Sofinnova Partners co-led the seed investment in 2019 and has supported the company from founding through to exit The proposed acquisition combines the oncology expertise of Novartis with Myricx Bio’s novel ADC assets and platform having broad potential across multiple solid tumor types Myricx Bio’s first-in-class NMTi payload platform is designed to improve the therapeutic […]